SG10201914022QA - Checkpoint blockade and microsatellite instability - Google Patents

Checkpoint blockade and microsatellite instability

Info

Publication number
SG10201914022QA
SG10201914022QA SG10201914022QA SG10201914022QA SG10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA
Authority
SG
Singapore
Prior art keywords
microsatellite instability
checkpoint blockade
checkpoint
blockade
microsatellite
Prior art date
Application number
SG10201914022QA
Inventor
Diaz Luis
Vogelstein Bert
W Kinzler Kenneth
Papadopoulos Nickolas
Le Dung
L Topalian Suzanne
M Pardoll Drew
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55955037&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914022Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG10201914022QA publication Critical patent/SG10201914022QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914022QA 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability SG10201914022QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079357P 2014-11-13 2014-11-13
US201562190977P 2015-07-10 2015-07-10

Publications (1)

Publication Number Publication Date
SG10201914022QA true SG10201914022QA (en) 2020-03-30

Family

ID=55955037

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914022QA SG10201914022QA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Country Status (9)

Country Link
US (14) US20170313775A1 (en)
EP (3) EP3888679A1 (en)
JP (4) JP2017537087A (en)
KR (5) KR20210069124A (en)
CN (2) CN106999582A (en)
AU (3) AU2015346295A1 (en)
CA (1) CA2966660A1 (en)
SG (2) SG10201914022QA (en)
WO (1) WO2016077553A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SG10201914022QA (en) 2014-11-13 2020-03-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
MA40737A (en) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
KR102492532B1 (en) 2015-05-29 2023-01-30 아게누스 인코포레이티드 Anti-CTLA-4 Antibodies and Methods of Using The Same
CN107949573B (en) 2015-09-01 2022-05-03 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
KR20180119632A (en) 2016-02-29 2018-11-02 제넨테크, 인크. Treatment and Diagnosis Methods for Cancer
JP2019509282A (en) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド How to treat cancer
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
KR20230047498A (en) * 2016-06-03 2023-04-07 브리스톨-마이어스 스큅 컴퍼니 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CA3038712A1 (en) * 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN117586403A (en) 2016-10-11 2024-02-23 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
ES2963226T3 (en) 2016-12-07 2024-03-26 Agenus Inc ANTI-CTLA-4 antibodies and methods of their use
CN106834479A (en) * 2017-02-16 2017-06-13 凯杰（苏州）转化医学研究有限公司 Microsatellite instability state analysis system in immunotherapy of tumors
AU2018243754A1 (en) * 2017-03-31 2019-10-17 Bristol-Myers Squibb Company Methods of treating tumor
CN117582495A (en) 2017-06-02 2024-02-23 拜耳医药保健有限责任公司 Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer
US11104938B2 (en) 2017-06-20 2021-08-31 Bio-Rad Laboratories, Inc. Digital amplification assays for genetic instability
KR20200093518A (en) 2017-07-21 2020-08-05 제넨테크, 인크. Methods of treatment and diagnosis for cancer
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
CA3079253A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
EP3717520A4 (en) 2017-12-01 2021-08-18 Personal Genome Diagnostics Inc. Process for microsatellite instability detection
CN108220405A (en) * 2018-02-06 2018-06-29 上海汇真生物科技有限公司 The method and kit of microsatellite stability state-detection
US20210047408A1 (en) 2018-02-13 2021-02-18 Merck Sharp & Dohme Corp. Methods for treating cancer with anti-pd-1 antibodies
SG11202100344WA (en) 2018-07-23 2021-02-25 Guardant Health Inc Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020021119A1 (en) * 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Method of monitoring effectiveness of immunotherapy of cancer patients
AU2019328344A1 (en) 2018-08-31 2021-04-08 Guardant Health, Inc. Microsatellite instability detection in cell-free DNA
US20200118644A1 (en) * 2018-10-15 2020-04-16 Tempus Labs, Inc. Microsatellite instability determination system and related methods
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
WO2020102674A1 (en) * 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
EP3997625A4 (en) * 2019-10-29 2022-11-09 Samsung Electronics Co., Ltd. Electronic apparatus and method for controlling thereof
US20220316015A1 (en) * 2019-12-18 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Method for determining if a tumor has a mutation in a microsatellite
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA43460A (en) 1893-07-03 Robert Wellington Bigger Furnace
CA62924A (en) 1898-12-27 1899-03-25 Azarie Mireault Medicinal compound
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
ATE466958T1 (en) * 2003-12-27 2010-05-15 Aros Applied Biotechnology As CLASSIFICATION OF COLON CANCER
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2007339897B2 (en) 2006-12-27 2013-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
RS54233B1 (en) 2008-08-25 2015-12-31 Amplimmune Inc. Compositions of pd-1 antagonists and methods of use
CN108484767B (en) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
JP5312684B2 (en) * 2009-05-04 2013-10-09 エフ．ホフマン−ラ ロシュ アーゲー Use of DPPIV / seprase as a marker for cancer
CN102230004B (en) * 2011-06-08 2012-12-26 北京阅微基因技术有限公司 Tumor cell microsatellite instable state complex amplification system and detection kit
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
SG10201704992SA (en) * 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
MX2016008771A (en) 2014-01-02 2016-12-20 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy.
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
SG10201914022QA (en) 2014-11-13 2020-03-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
KR20230047498A (en) 2016-06-03 2023-04-07 브리스톨-마이어스 스큅 컴퍼니 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CA2935432A1 (en) 2016-07-07 2018-01-07 Georgios Gerardos Immunoassay detection device

Also Published As

Publication number Publication date
US20210130463A1 (en) 2021-05-06
US20220259312A1 (en) 2022-08-18
US20170313775A1 (en) 2017-11-02
JP2023053140A (en) 2023-04-12
EP4098278A1 (en) 2022-12-07
KR20220054710A (en) 2022-05-03
WO2016077553A1 (en) 2016-05-19
US11325975B2 (en) 2022-05-10
EP3218004A4 (en) 2018-06-13
AU2021202086A1 (en) 2021-04-29
EP3218004A1 (en) 2017-09-20
US20220056129A1 (en) 2022-02-24
US20190023787A1 (en) 2019-01-24
JP2017537087A (en) 2017-12-14
AU2019201671A1 (en) 2019-04-04
SG11201703541PA (en) 2017-05-30
US11339219B2 (en) 2022-05-24
CN113694193A (en) 2021-11-26
CN106999582A (en) 2017-08-01
US20230365677A1 (en) 2023-11-16
KR20230030022A (en) 2023-03-03
EP3888679A1 (en) 2021-10-06
US20220275086A1 (en) 2022-09-01
US11753468B2 (en) 2023-09-12
AU2015346295A1 (en) 2017-05-25
US20210155693A1 (en) 2021-05-27
US11643462B2 (en) 2023-05-09
US20210324077A1 (en) 2021-10-21
US20170267760A1 (en) 2017-09-21
KR20170080697A (en) 2017-07-10
US11718668B2 (en) 2023-08-08
JP2021095410A (en) 2021-06-24
US20210324078A1 (en) 2021-10-21
US11634491B2 (en) 2023-04-25
US11649287B2 (en) 2023-05-16
KR20210069124A (en) 2021-06-10
US11325974B2 (en) 2022-05-10
US20230026716A1 (en) 2023-01-26
CA2966660A1 (en) 2016-05-19
US11591393B2 (en) 2023-02-28
US10934356B2 (en) 2021-03-02
KR20190135563A (en) 2019-12-06
US20210395365A1 (en) 2021-12-23
US11629187B2 (en) 2023-04-18
JP2019142881A (en) 2019-08-29
US20210107978A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
SG11201703541PA (en) Checkpoint blockade and microsatellite instability
IL280791A (en) Deuterated compounds and uses thereof
ZA201608889B (en) Residence structures and related methods
HK1243073A1 (en) Therapeutic compounds and uses thereof
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
FI3215147T3 (en) Neuro-attenuating norketamine compounds and methods
GB201516882D0 (en) Methods and systems for updating user profiles
GB201413355D0 (en) Compositons and methods
HUE044571T2 (en) Modified cyclopentapeptides and uses thereof
GB201408727D0 (en) Improved plasmonic structures and devices
GB201404470D0 (en) Therapeutic methods and materials
SG11201704498QA (en) Computing systems and methods
SG11201704473WA (en) New methods and uses
HK1243342A1 (en) Compounds and methods
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
EP3214323A4 (en) Fastening structure and fastening method
GB201517786D0 (en) Methods and materials
GB201408091D0 (en) Methods and uses
PL3145465T3 (en) Closure assemblies using extended fingerlifts
GB2530711B (en) Security composition and use thereof
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses
GB201407599D0 (en) New compounds and uses